Literature DB >> 21264764

Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: report of a case.

Fumihiro Shoji1, Daigo Kawano, Kensaku Ito, Yosuke Morodomi, Tokujiro Yano, Yoshihiko Maehara.   

Abstract

We report a case of recurrent pulmonary adenocarcinoma, found 2 years after resection, which responded extremely well to erlotinib, after gefitinib treatment had failed to evoke any response. This case report provides useful information for thoracic oncologists and shows that we should consider giving erlotinib after gefitinib for recurrent pulmonary adenocarcinoma, even if the gefitinib treatment is ineffective.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21264764     DOI： 10.1007/s00595-009-4259-3

Source DB:  PubMed          Journal:  Surg Today        ISSN： 0941-1291            Impact factor:   2.549


  10 in total

1.  Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.

Authors:  Shang-Gin Wu; Jin-Yuan Shih; Chong-Jen Yu; Pan-Chyr Yang
Journal:  J Thorac Oncol       Date:  2008-04       Impact factor: 15.609

2.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

3.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

Authors:  Tetsuya Mitsudomi; Takayuki Kosaka; Hideki Endoh; Yoshitsugu Horio; Toyoaki Hida; Shoichi Mori; Shunzo Hatooka; Masayuki Shinoda; Takashi Takahashi; Yasushi Yatabe
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

4.  Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.

Authors:  Nicholas W Choong; Sascha Dietrich; Tanguy Y Seiwert; Maria S Tretiakova; Vidya Nallasura; Gareth C Davies; Stanley Lipkowitz; Aliya N Husain; Ravi Salgia; Patrick C Ma
Journal:  Nat Clin Pract Oncol       Date:  2006-01

5.  Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.

Authors:  Byoung Chul Cho; Chong-Kun Im; Moo-Suk Park; Se Kyu Kim; Joon Chang; Jong Pil Park; Hye Jin Choi; Yu Jin Kim; Sang-Joon Shin; Joo Hyuk Sohn; Hoguen Kim; Joo Hang Kim
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

Review 6.  The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.

Authors:  Robert L Comis
Journal:  Oncologist       Date:  2005-08

7.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

8.  Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.

Authors:  John Wen-Cheng Chang; Chun-Liang Chou; Shiu-Feng Huang; Hung-Ming Wang; Jia-Juan Hsieh; Todd Hsu; Yun-Chung Cheung
Journal:  Lung Cancer       Date:  2007-07-06       Impact factor: 5.705

9.  Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.

Authors:  Alvin S Wong; Richie Soong; Serena Bee-Kee Seah; Siew-Woon Lim; Khoon-Leong Chuah; Min-En Nga; Tan-Min Chin; Ross A Soo
Journal:  J Thorac Oncol       Date:  2008-04       Impact factor: 15.609

10.  The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.

Authors:  F Shoji; T Yano; I Yoshino; D Mori; F Yamasaki; H Kohno; Y Maehara
Journal:  Eur J Surg Oncol       Date:  2007-04-20       Impact factor: 4.424
  10 in total
  1 in total

Review 1.  Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature.

Authors:  Navneet Singh; Aditya Jindal; Digambar Behera
Journal:  World J Clin Oncol       Date:  2014-12-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.